XRTX
HEALTHCAREXORTX Therapeutics Inc
$2.76-0.01 (-0.36%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving XRTX Today?
No stock-specific AI insight has been generated for XRTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.73$7.05
$2.76
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-2.80
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume12K
Avg Volume (10D)—
Shares Outstanding1.5M
XRTX News
20 articles- XORTX Meets Nasdaq Continued Listing RequirementsYahoo Finance·Apr 21, 2026
- XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic AssetGlobeNewswire Inc.·Apr 13, 2026
- XORTX Confirms Effective Date of Share ConsolidationGlobeNewswire Inc.·Apr 1, 2026
- XORTX Announces Results of Annual and Special Meeting of ShareholdersGlobeNewswire Inc.·Mar 26, 2026
- XORTX Announces Change of Effective Date of Share ConsolidationYahoo Finance·Mar 26, 2026
- XORTX Announces Share ConsolidationYahoo Finance·Mar 25, 2026
- XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General MeetingGlobeNewswire Inc.·Mar 24, 2026
- XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of ShareholdersYahoo Finance·Mar 18, 2026
- XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share ConsolidationYahoo Finance·Mar 13, 2026
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of ShareholdersYahoo Finance·Mar 5, 2026
- XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus BiosystemsYahoo Finance·Feb 4, 2026
- XORTX Therapeutics Says Published Research Supports Company Approach to Gout TreatmentYahoo Finance·Jan 2, 2026
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate UpdateYahoo Finance·Dec 31, 2025
- XORTX Announces Closing of US$1.1 Million Registered Direct OfferingYahoo Finance·Oct 29, 2025
- XORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct OfferingYahoo Finance·Oct 21, 2025
- XORTX Announces Pricing of US$1.1 Million Registered Direct OfferingYahoo Finance·Oct 21, 2025
- MT Newswires Canada Overnight Stocks To Watch: Allied Gold; Lithium Americas; XORTX TherapeuticsYahoo Finance·Oct 21, 2025
- XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price DeficiencyYahoo Finance·Oct 21, 2025
- XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyYahoo Finance·Oct 20, 2025
- XORTX Therapeutics Jumps 45% on US$3 Million Deal to Buy Renal Program From Vectus BiosystemsYahoo Finance·Oct 17, 2025
All 20 articles loaded
Price Data
Open$2.80
Previous Close$2.77
Day High$2.84
Day Low$2.73
52 Week High$7.05
52 Week Low$1.73
52-Week Range
$1.73$7.05
$2.76
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-2.80
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume12K
Avg Volume (10D)—
Shares Outstanding1.5M
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease, hypertension, insulin resistance, and diabetic nephropathy. The company is headquartered in Vancouver, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—